Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status

Background: Leptomeningeal metastasis (LM) is a catastrophic complication for patients with non-small cell lung cancer (NSCLC) and carries an extremely poor prognosis. The efficacy of osimertinib 80 mg once daily for epidermal growth factor receptor-mutated (EGFRm) NSCLC with LM has yet to be fully...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of translational medicine 2021-06, Vol.9 (11), p.937-937, Article 937
Hauptverfasser:	Xu, Haiyan, Chen, Hengqi, Kong, Jianxin, Zhang, Ye, Liu, Shan, Yang, Guangjian, Yang, Lu, Wang, Yan
Format:	Artikel
Sprache:	eng
Schlagworte:	Life Sciences & Biomedicine Medicine, Research & Experimental Oncology Original Research & Experimental Medicine Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!